Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share (CNTA) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2021 to Q4 2025

Type / Class
Equity / Ordinary shares, par value 0.002 GBP per share
Symbol
CNTA on Nasdaq
Shares outstanding
147,336,360
Price per share
$25.01
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
128,332,503
Total reported value
$3,111,987,564
% of total 13F portfolios
0.01%
Share change
+4,797,200
Value change
+$147,803,679
Number of holders
124
Price from insider filings
$25.01
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share (CNTA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Avoro Capital Advisors LLC 8.1% $262,095,940 10,808,080 Avoro Capital Advisors LLC 30 Sep 2025
Adage Capital Management, L.P. 7.5% +20% $243,348,750 +$39,576,000 10,035,000 +19% Adage Capital Management, L.P. 30 Sep 2025
General Atlantic Cooperatief U.A. 5% -23% $180,192,368 -$56,624,900 7,366,818 -24% General Atlantic Cooperatief U.A. 25 Nov 2025
FMR LLC 7% $152,223,143 6,277,243 FMR LLC 30 Sep 2025

As of 30 Sep 2025, 124 institutional investors reported holding 128,332,503 shares of Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share (CNTA). This represents 87% of the company’s total 147,336,360 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share (CNTA) together control 77% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Medicxi Ventures Management (Jersey) Ltd 14% 19,963,157 0% 65% $484,106,557
Avoro Capital Advisors LLC 7.3% 10,808,080 +116% 3.4% $262,095,940
ADAGE CAPITAL PARTNERS GP, L.L.C. 6.8% 10,035,000 +19% 0.39% $243,348,750
Index Venture Life Associates VI Ltd 6.8% 9,961,789 0% 100% $241,573,383
GENERAL ATLANTIC, L.P. 6.6% 9,681,818 0% 7% $234,784,087
FMR LLC 4.3% 6,277,243 +64% 0.01% $152,223,143
JANUS HENDERSON GROUP PLC 3.7% 5,408,199 -17% 0.06% $131,075,198
PRICE T ROWE ASSOCIATES INC /MD/ 3.3% 4,804,056 -19% 0.01% $116,499,000
FARALLON CAPITAL MANAGEMENT LLC 2.9% 4,331,318 -4.4% 0.59% $105,034,462
First Light Asset Management, LLC 2.5% 3,635,816 -15% 8.3% $88,168,538
Siren, L.L.C. 2.2% 3,227,517 -6.7% 3.1% $78,267,287
TCG Crossover Management, LLC 2.1% 3,136,480 +8.5% 3.7% $76,059,640
PERCEPTIVE ADVISORS LLC 2.1% 3,100,902 +170% 2.2% $75,196,874
Commodore Capital LP 1.9% 2,850,000 -14% 3.4% $69,112,500
FRANKLIN RESOURCES INC 1.7% 2,558,414 +0.58% 0.02% $62,041,541
RTW INVESTMENTS, LP 1.6% 2,291,747 +50% 0.68% $55,574,865
Cormorant Asset Management, LP 1.3% 1,925,000 -7.7% 3.2% $46,681,250
FEDERATED HERMES, INC. 1.2% 1,749,650 0.07% $42,429,013
Foresite Capital Management VI LLC 0.89% 1,314,019 +4.8% 12% $31,864,961
MORGAN STANLEY 0.76% 1,124,445 -37% 0% $27,267,792
Affinity Asset Advisors, LLC 0.75% 1,107,162 +23% 2.5% $26,848,679
AMERICAN CENTURY COMPANIES INC 0.74% 1,096,704 -3% 0.01% $26,595,131
Point72 Asset Management, L.P. 0.73% 1,072,665 -59% 0.06% $26,012,126
MILLENNIUM MANAGEMENT LLC 0.61% 902,268 -46% 0.02% $21,879,999
Octagon Capital Advisors LP 0.56% 830,000 -19% 3.1% $20,127,500

Institutional Holders of Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share (CNTA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 268,380 $6,711,914 +$4,709,421 $25.01 5
2025 Q3 128,332,503 $3,111,987,564 +$147,803,679 $24.25 124
2025 Q2 123,569,478 $1,623,678,828 -$30,690,539 $13.14 117
2025 Q1 124,913,742 $1,797,461,231 -$6,439,160 $14.38 130
2024 Q4 124,413,136 $2,083,915,345 +$72,898,202 $16.75 114
2024 Q3 108,571,980 $1,737,489,847 +$315,516,266 $15.99 101
2024 Q2 86,506,981 $781,158,600 +$108,671,569 $9.03 79
2024 Q1 74,395,267 $840,663,455 +$66,659,727 $11.30 69
2023 Q4 71,279,084 $567,382,245 +$15,317,885 $7.96 56
2023 Q3 72,578,425 $469,582,127 +$14,480,766 $6.47 46
2023 Q2 70,339,619 $435,403,089 +$25,413,534 $6.19 43
2023 Q1 66,895,058 $257,540,618 +$13,125,714 $3.85 42
2022 Q4 62,684,642 $194,353,719 +$5,918,047 $3.10 41
2022 Q3 71,808,783 $288,649,039 -$842,289 $4.02 41
2022 Q2 71,775,040 $349,577,531 -$37,633,222 $4.87 40
2022 Q1 74,581,035 $669,057,512 +$23,146,015 $8.97 40
2021 Q4 71,873,880 $807,766,000 +$18,577,946 $11.26 46
2021 Q3 52,983,439 $881,813,000 +$147,088,157 $16.70 38
2021 Q2 47,409,892 $1,045,414,000 +$1,045,413,999 $22.21 49